Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332334 | 0.74 | GRM2 (0.58) | GRM2ALDH1A1POLBHTTRAB9A | |
| SCHEMBL4332336 | 0.74 | GRM2 (0.58) | GRM2ALDH1A1POLBHTTRAB9A | |
| SCHEMBL4096799 | 0.74 | GRM2 (0.58) | GRM2ALDH1A1POLBHTTRAB9A | |
| SCHEMBL4088740 | 0.72 | HSD11B1 (0.48) | ALDH1A1 | |
| SCHEMBL9767014 | 0.69 | GRM2 (0.51) | GRM2ALDH1A1POLBHTTRAB9A | |
| SCHEMBL4002061 | 0.66 | ALDH1A1 (0.47) | GRM2ALDH1A1POLBHTTRAB9A | |
| SCHEMBL17238332 | 0.65 | MMP1 (0.43) | GRM2AROPRM1MMP1MMP13 | |
| SCHEMBL15819471 | 0.65 | MMP1 (0.43) | GRM2AROPRM1MMP1MMP13 | |
| SCHEMBL17238331 | 0.65 | MMP1 (0.43) | GRM2AROPRM1MMP1MMP13 | |
| SCHEMBL3910514 | 0.65 | ALDH1A1 (0.49) | GRM2ALDH1A1POLBHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | GRM2 1761/4885ALDH1A1 785/4885POLB 3961/4885 |
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | GRM2 2261/4885ALDH1A1 159/4885POLB 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.